Salarius Pharmaceuticals (Salarius Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Salarius Pharmaceuticals's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Salarius Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.73.

Salarius Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Salarius Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Accounts Receivable Chart

Salarius Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Salarius Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Salarius Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Salarius Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Salarius Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Salarius Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Salarius Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.373	+	0.75 * 0	+	0.5 * 0	-	1.234
-	0	-	0)	/	4.31443
=	0.73

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Salarius Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

FP1:Germany

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Executives

Tess Burleson	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber	director	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum	officer: Exec VP Finance, Interim CFO	3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur	director, officer: Chief Executive Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan	officer: Chief Financial Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr.	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang	officer: Controller	2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers	director	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc.	10 percent owner	75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal	10 percent owner	C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p.	10 percent owner	800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421